Circulating Galectin-3 Levels Are Persistently Elevated After Heart Transplantation and Are Associated With Renal Dysfunction

JACC: Heart Failure

Volumn 4, Issue 11, 2016, Pages 847-856

  Grupper, Avishay ^a   Nativi Nicolau, Jose ^a   Maleszewski, Joseph J ^a   Geske, Jennifer R ^a   Kremers, Walter K ^a   Edwards, Brooks S ^a   Kushwaha, Sudhir S ^a   Pereira, Naveen L ^a  

^a MAYO CLINIC   (United States)

Author keywords

exercise capacity; galectin 3; heart failure; heart transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; GALECTIN 3; MYCOPHENOLATE MOFETIL; PREDNISONE; TACROLIMUS; GALECTIN-3, HUMAN;

ADULT; ALLOGRAFT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; HEART; HEART FUNCTION; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HEART VENTRICLE HYPERTROPHY; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRANSTHORACIC ECHOCARDIOGRAPHY; AGED; CARDIAC MUSCLE; COMPLICATION; EXERCISE TOLERANCE; FEMALE; FIBROSIS; HEART FAILURE; HYPERTROPHY; KIDNEY FAILURE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; EXERCISE TOLERANCE; FEMALE; FIBROSIS; GALECTIN 3; GLOMERULAR FILTRATION RATE; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; HYPERTROPHY; MALE; MIDDLE AGED; MYOCARDIUM; PROGNOSIS; RENAL INSUFFICIENCY;

EID: 84994083489     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.06.010     Document Type: Article

References (39)

1. 1 Dhirapong, A., Lleo, A., Leung, P., Gershwin, M.E., Liu, F.T., The immunological potential of galectin-1 and -3. Autoimmun Rev 8 (2009), 360–363.
2. 2 Henderson, N.C., Sethi, T., The regulation of inflammation by galectin-3. Immunol Rev 230 (2009), 160–171.
3. 3 de Boer, R.A., Voors, A.A., Muntendam, P., van Gilst, W.H., van Veldhuisen, D.J., Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 11 (2009), 811–817.
4. 4 Sharma, U.C., Pokharel, S., van Brakel, T.J., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110 (2004), 3121–3128.
5. 5 Yu, L., Ruifrok, W.P., Meissner, M., et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 6 (2013), 107–117.
6. 6 Lok, D.J., Van Der Meer, P., de la Porte, P.W., et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure. Clin Res Cardiol 99 (2010), 323–328.
7. 7 Shah, R.V., Chen-Tournoux, A.A., Picard, M.H., van Kimmenade, R.R., Januzzi, J.L., Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 12 (2010), 826–832.
8. 8 de Boer, R.A., Lok, D.J., Jaarsma, T., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43 (2011), 60–68.
9. 9 Ho, J.E., Liu, C., Lyass, A., et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 60 (2012), 1249–1256.
10. 10 de Boer, R.A., van Veldhuisen, D.J., Gansevoort, R.T., et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 272 (2012), 55–64.
11. 11 Gopal, D.M., Kommineni, M., Ayalon, N., et al. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc, 1, 2012, e000760.
12. 12 Tang, W.H., Shrestha, K., Shao, Z., et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 108 (2011), 385–390.
13. 13 Meijers, W.C., Januzzi, J.L., deFilippi, C., et al. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am Heart J 167 (2014), 853–860.
14. 14 Berry, G.J., Angelini, A., Burke, M.M., et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J Heart Lung Transplant 30 (2011), 601–611.
15. 15 Stewart, S., Winters, G.L., Fishbein, C., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 24 (2005), 1710–1720.
16. 16 Daida, H., Allison, T.G., Johnson, B.D., Squires, R.W., Gau, G.T., Comparison of peak exercise oxygen uptake in men versus women in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 80 (1997), 85–88.
17. 17 Lin, Y.H., Lin, L.Y., Wu, Y.W., et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 409 (2009), 96–99.
18. 18 Frunza, O., Russo, I., Saxena, A., et al. Myocardial galectin-3 expression is associated with remodeling of the pressure-overloaded heart and may delay the hypertrophic response without affecting survival, dysfunction, and cardiac fibrosis. Am J Pathol 186 (2016), 1114–1127.
19. 19 Abou Ezzeddine, O.F., Haines, P., Stevens, S., et al. Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). J Am Coll Cardiol HF 3 (2015), 245–252.
20. 20 Armstrong, A.T., Binkley, P.F., Baker, P.B., Myerowitz, P.D., Leier, C.V., Quantitative investigation of cardiomyocyte hypertrophy and myocardial fibrosis over 6 years after cardiac transplantation. J Am Coll Cardiol 32 (1998), 704–710.
21. 21 Kobashigawa, J.A., Itagaki, B.K., Razi, R.R., et al. Correlation between myocardial fibrosis and restrictive cardiac physiology in patients undergoing retransplantation. Clin Transplant 27 (2013), E679–E684.
22. 22 Beiras-Fernandez, A., Weis, F., Rothkopf, J., et al. Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation. Ann Transplant 18 (2013), 643–650.
23. 23 van der Velde, A.R., Gullestad, L., Ueland, T., et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 6 (2013), 219–226.
24. 24 Anand, I.S., Rector, T.S., Kuskowski, M., Adourian, A., Muntendam, P., Cohn, J.N., Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 15 (2013), 511–518.
25. 25 Motiwala, S.R., Szymonifka, J., Belcher, A., et al. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail 15 (2013), 1157–1163.
26. 26 Lopez-Andrès, N., Rossignol, P., Iraqi, W., et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 14 (2012), 74–81.
27. 27 Milting, H., Ellinghaus, P., Seewald, M., et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 27 (2008), 589–596.
28. 28 Bayes-Genis, A., de Antonio, M., Vila, J., et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol 63 (2014), 158–166.
29. 29 Hussain I, Alexander MP, Maleszewski JJ, Pereira NL, Redfield MM. Galectin-3 in the pathophysiology of heart failure: novel insights into the renal connection [abstract]. In Proceedings of the American Heart Association Congress. November 2015, Orlando, FL.
30. 30 Felker, G.M., Fiuzat, M., Shaw, L.K., et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 5 (2012), 72–78.
31. 31 Leung, T.C., Ballman, K.V., Allison, T.G., et al. Clinical predictors of exercise capacity 1 year after cardiac transplantation. J Heart Lung Transplant 22 (2003), 16–27.
32. 32 Raichlin, E., Al-Omari, M.A., Hayes, C.L., et al. Cardiac allograft hypertrophy is associated with impaired exercise tolerance after heart transplantation. J Heart Lung Transplant 30 (2011), 1153–1160.
33. 33 Patel, A.R., Kuvin, J.T., DeNofrio, D., et al. Peripheral vascular endothelial function correlates with exercise capacity in cardiac transplant recipients. Am J Cardiol 91 (2003), 897–899.
34. 34 Raichlin, E., Villarraga, H.R., Chandrasekaran, K., et al. Cardiac allograft remodeling after heart transplantation is associated with increased graft vasculopathy and mortality. Am J Transplant 9 (2009), 132–139.
35. 35 Ojo, A.O., Held, P.J., Port, F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349 (2003), 931–940.
36. 36 Thomas, H.L., Banner, N.R., Murphy, C.L., et al., Steering Group of the UK Cardiothoracic Transplant Audit. Incidence, determinants, and outcome of chronic kidney disease after adult heart transplantation in the United Kingdom. Transplantation 93 (2012), 1151–1157.
37. 37 Al Aly, Z., Abbas, S., Moore, E., Diallo, O., Hauptman, P.J., Bastani, B., The natural history of renal function following orthotopic heart transplant. Clin Transplant 19 (2005), 683–689.
38. 38 Van Laethem, C., Bartunek, J., Goethals, M., et al. Chronic kidney disease is associated with decreased exercise capacity and impaired ventilatory efficiency in heart transplantation patients. J Heart Lung Transplant 28 (2009), 446–452.
39. 39 Darrow, A.L., Shohet, R.V., Maresh, J.G., Transcriptional analysis of the endothelial response to diabetes reveals a role for galectin-3. Physiol Genomics 43 (2011), 1144–1152.